PLUR.US Pluri Inc.

Healthcare Biotechnology USA Stocks
1.05 USD
Close of Nov 15, 2026
0.8500 4.12
Market cap
USD 15.1M
P/E
-
P/B
306.56x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is PLUR.US undervalued?

Graham number

The Graham number of Pluri Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pluri Inc. fundamental analysis

No fundamental analysis for Pluri Inc. yet.

Pluri Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pluri Inc.

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the …

Full company profile